Marburg virus: Scientists start human testing of vaccine

The Oxford Vaccine Group has administered the vaccine to people aged between 18 and 55.

The trial is being funded by the Department of Health and Social Care as part of the UK Vaccine Network (UKVN), a UK Aid programme developing vaccines for diseases with epidemic potential in low and middle-income countries.

Professor Teresa Lambe OBE is lead scientific investigator, she said: “Although outbreaks of Marburg virus have historically been small, this devastating disease has started to spread even further and the potential to cause a pandemic and inflict suffering on many is a real concern.”

There have been multiple outbreaks of the disease across Sub-Saharan Africa, including Tanzania and Equatorial Guinea in 2023.

The virus can be transmitted between humans through direct contact and bodily fluids which means health workers are most likely to get infected.

It can hamper the blood’s ability to clot which could result in internal bleeding and can also lead to inflammation of the brain.

It has an estimated case fatality rate of up to 88% based on previous outbreaks.

Professor Lambe said: “With no approved treatments for Marburg, developing a vaccine is critical.

“This Oxford trial is a first step towards developing a safe and effective vaccine to protect people from future outbreaks.”